(IR) Ingersoll Rand - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45687V1061
Stock: Air Compressors, Pumps, Power Tools, Gas Boosters, Fluid Transfer
Total Rating 47
Risk 69
Buy Signal -0.43
| Risk 5d forecast | |
|---|---|
| Volatility | 30.8% |
| Relative Tail Risk | -9.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.10 |
| Alpha | -20.87 |
| Character TTM | |
|---|---|
| Beta | 1.216 |
| Beta Downside | 1.316 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.62% |
| CAGR/Max DD | 0.46 |
EPS (Earnings per Share)
Revenue
Description: IR Ingersoll Rand March 04, 2026
Ingersoll Rand Inc. (IR) supplies essential industrial technologies and services globally. The company operates in two primary segments: Industrial Technologies and Services, and Precision and Science Technologies.
The Industrial Technologies and Services segment focuses on air and gas compression, vacuum, and fluid transfer equipment, along with power tools and lifting equipment. This sector typically involves high capital expenditure for clients and a recurring revenue stream from aftermarket parts and services.
The Precision and Science Technologies segment manufactures various pump types and specialized systems for precision dosing and fluid control. Products from this segment serve diverse markets, including medical, laboratory, and clean energy, reflecting a business model often characterized by specialized engineering and customized solutions.
IR distributes its products via direct sales and independent distributors. For a deeper dive into IRs valuation and market position, consider exploring ValueRay.
Headlines to watch out for
- Industrial technologies and services segment drives core revenue growth
- Precision and science technologies segment expands into high-growth markets
- Aftermarket parts and services provide recurring revenue stream
- Global industrial production and capital expenditure influence demand
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 581.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.59 > 1.0 |
| NWC/Revenue: 28.52% < 20% (prev 32.41%; Δ -3.89% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.36b > Net Income 581.4m |
| Net Debt (3.54b) to EBITDA (1.69b): 2.09 < 3 |
| Current Ratio: 2.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (395.8m) vs 12m ago -2.76% < -2% |
| Gross Margin: 38.54% > 18% (prev 0.44%; Δ 3810 % > 0.5%) |
| Asset Turnover: 42.15% > 50% (prev 40.17%; Δ 1.97% > 0%) |
| Interest Coverage Ratio: 4.68 > 6 (EBITDA TTM 1.69b / Interest Expense TTM 253.9m) |
Altman Z'' 2.14
| A: 0.12 (Total Current Assets 4.25b - Total Current Liabilities 2.07b) / Total Assets 18.30b |
| B: 0.17 (Retained Earnings 3.05b / Total Assets 18.30b) |
| C: 0.07 (EBIT TTM 1.19b / Avg Total Assets 18.15b) |
| D: 0.36 (Book Value of Equity 2.91b / Total Liabilities 8.14b) |
| Altman-Z'' Score: 2.14 = BBB |
Beneish M -2.85
| DSRI: 1.07 (Receivables 1.52b/1.34b, Revenue 7.65b/7.24b) |
| GMI: 1.14 (GM 38.54% / 43.81%) |
| AQI: 0.99 (AQ_t 0.72 / AQ_t-1 0.72) |
| SGI: 1.06 (Revenue 7.65b / 7.24b) |
| TATA: -0.04 (NI 581.4m - CFO 1.36b) / TA 18.30b) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of IR shares?
As of March 10, 2026, the stock is trading at USD 86.66 with a total of 2,748,369 shares traded.
Over the past week, the price has changed by -7.76%, over one month by -11.90%, over three months by +10.59% and over the past year by +3.86%.
Over the past week, the price has changed by -7.76%, over one month by -11.90%, over three months by +10.59% and over the past year by +3.86%.
Is IR a buy, sell or hold?
Ingersoll Rand has received a consensus analysts rating of 3.94.
Therefore, it is recommended to buy IR.
- StrongBuy: 7
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.1 | 17.8% |
| Analysts Target Price | 102.1 | 17.8% |
IR Fundamental Data Overview March 06, 2026
P/E Trailing = 63.3379
P/E Forward = 26.3852
P/S = 4.7428
P/B = 3.6473
P/EG = 0.8708
Revenue TTM = 7.65b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.69b USD
Long Term Debt = 4.78b USD (from longTermDebt, last quarter)
Short Term Debt = 1.40m USD (from shortTermDebt, last quarter)
Debt = 4.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.54b USD (from netDebt column, last quarter)
Enterprise Value = 39.82b USD (36.29b + Debt 4.78b - CCE 1.25b)
Interest Coverage Ratio = 4.68 (Ebit TTM 1.19b / Interest Expense TTM 253.9m)
EV/FCF = 32.64x (Enterprise Value 39.82b / FCF TTM 1.22b)
FCF Yield = 3.06% (FCF TTM 1.22b / Enterprise Value 39.82b)
FCF Margin = 15.95% (FCF TTM 1.22b / Revenue TTM 7.65b)
Net Margin = 7.60% (Net Income TTM 581.4m / Revenue TTM 7.65b)
Gross Margin = 38.54% ((Revenue TTM 7.65b - Cost of Revenue TTM 4.70b) / Revenue TTM)
Gross Margin QoQ = 24.06% (prev 43.74%)
Tobins Q-Ratio = 2.18 (Enterprise Value 39.82b / Total Assets 18.30b)
Interest Expense / Debt = 1.36% (Interest Expense 64.9m / Debt 4.78b)
Taxrate = 19.81% (66.3m / 334.7m)
NOPAT = 952.2m (EBIT 1.19b * (1 - 19.81%))
Current Ratio = 2.06 (Total Current Assets 4.25b / Total Current Liabilities 2.07b)
Debt / Equity = 0.47 (Debt 4.78b / totalStockholderEquity, last quarter 10.09b)
Debt / EBITDA = 2.09 (Net Debt 3.54b / EBITDA 1.69b)
Debt / FCF = 2.90 (Net Debt 3.54b / FCF TTM 1.22b)
Total Stockholder Equity = 10.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 581.4m / Total Assets 18.30b)
RoE = 5.70% (Net Income TTM 581.4m / Total Stockholder Equity 10.20b)
RoCE = 7.93% (EBIT 1.19b / Capital Employed (Equity 10.20b + L.T.Debt 4.78b))
RoIC = 6.36% (NOPAT 952.2m / Invested Capital 14.98b)
WACC = 9.32% (E(36.29b)/V(41.07b) * Re(10.40%) + D(4.78b)/V(41.07b) * Rd(1.36%) * (1-Tc(0.20)))
Discount Rate = 10.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.53%
[DCF] Terminal Value 77.11% ; FCFF base≈1.25b ; Y1≈1.55b ; Y5≈2.64b
[DCF] Fair Price = 80.68 (EV 35.13b - Net Debt 3.54b = Equity 31.60b / Shares 391.6m; r=9.32% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 84.54 | EPS CAGR: 19.64% | SUE: 1.37 | # QB: 1
Revenue Correlation: 91.20 | Revenue CAGR: 12.67% | SUE: 2.19 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.86 | Chg7d=-0.001 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=14
EPS current Year (2026-12-31): EPS=3.54 | Chg7d=-0.008 | Chg30d=-0.021 | Revisions Net=-5 | Growth EPS=+5.9% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=3.89 | Chg7d=-0.011 | Chg30d=-0.029 | Revisions Net=+0 | Growth EPS=+10.0% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: -0.20 (2 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.8% (Discount Rate 10.4% - Earnings Yield 1.6%)
[Growth] Growth Spread = -3.9% (Analyst 5.0% - Implied 8.8%)
P/E Forward = 26.3852
P/S = 4.7428
P/B = 3.6473
P/EG = 0.8708
Revenue TTM = 7.65b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.69b USD
Long Term Debt = 4.78b USD (from longTermDebt, last quarter)
Short Term Debt = 1.40m USD (from shortTermDebt, last quarter)
Debt = 4.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.54b USD (from netDebt column, last quarter)
Enterprise Value = 39.82b USD (36.29b + Debt 4.78b - CCE 1.25b)
Interest Coverage Ratio = 4.68 (Ebit TTM 1.19b / Interest Expense TTM 253.9m)
EV/FCF = 32.64x (Enterprise Value 39.82b / FCF TTM 1.22b)
FCF Yield = 3.06% (FCF TTM 1.22b / Enterprise Value 39.82b)
FCF Margin = 15.95% (FCF TTM 1.22b / Revenue TTM 7.65b)
Net Margin = 7.60% (Net Income TTM 581.4m / Revenue TTM 7.65b)
Gross Margin = 38.54% ((Revenue TTM 7.65b - Cost of Revenue TTM 4.70b) / Revenue TTM)
Gross Margin QoQ = 24.06% (prev 43.74%)
Tobins Q-Ratio = 2.18 (Enterprise Value 39.82b / Total Assets 18.30b)
Interest Expense / Debt = 1.36% (Interest Expense 64.9m / Debt 4.78b)
Taxrate = 19.81% (66.3m / 334.7m)
NOPAT = 952.2m (EBIT 1.19b * (1 - 19.81%))
Current Ratio = 2.06 (Total Current Assets 4.25b / Total Current Liabilities 2.07b)
Debt / Equity = 0.47 (Debt 4.78b / totalStockholderEquity, last quarter 10.09b)
Debt / EBITDA = 2.09 (Net Debt 3.54b / EBITDA 1.69b)
Debt / FCF = 2.90 (Net Debt 3.54b / FCF TTM 1.22b)
Total Stockholder Equity = 10.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 581.4m / Total Assets 18.30b)
RoE = 5.70% (Net Income TTM 581.4m / Total Stockholder Equity 10.20b)
RoCE = 7.93% (EBIT 1.19b / Capital Employed (Equity 10.20b + L.T.Debt 4.78b))
RoIC = 6.36% (NOPAT 952.2m / Invested Capital 14.98b)
WACC = 9.32% (E(36.29b)/V(41.07b) * Re(10.40%) + D(4.78b)/V(41.07b) * Rd(1.36%) * (1-Tc(0.20)))
Discount Rate = 10.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.53%
[DCF] Terminal Value 77.11% ; FCFF base≈1.25b ; Y1≈1.55b ; Y5≈2.64b
[DCF] Fair Price = 80.68 (EV 35.13b - Net Debt 3.54b = Equity 31.60b / Shares 391.6m; r=9.32% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 84.54 | EPS CAGR: 19.64% | SUE: 1.37 | # QB: 1
Revenue Correlation: 91.20 | Revenue CAGR: 12.67% | SUE: 2.19 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.86 | Chg7d=-0.001 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=14
EPS current Year (2026-12-31): EPS=3.54 | Chg7d=-0.008 | Chg30d=-0.021 | Revisions Net=-5 | Growth EPS=+5.9% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=3.89 | Chg7d=-0.011 | Chg30d=-0.029 | Revisions Net=+0 | Growth EPS=+10.0% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: -0.20 (2 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.8% (Discount Rate 10.4% - Earnings Yield 1.6%)
[Growth] Growth Spread = -3.9% (Analyst 5.0% - Implied 8.8%)